<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Humana Press</PublisherName>
    <PublisherLocation>Totowa, NJ</PublisherLocation>
  </PublisherInfo>
  <Series>
    <SeriesInfo SeriesType="Series" TocLevels="0">
      <SeriesID>7651</SeriesID>
      <SeriesPrintISSN>1064-3745</SeriesPrintISSN>
      <SeriesElectronicISSN>1940-6029</SeriesElectronicISSN>
      <SeriesTitle Language="En">Methods in Molecular Biology™</SeriesTitle>
    </SeriesInfo>
    <SeriesHeader>
      <EditorGroup>
        <Editor AffiliationIDS="Aff1">
          <EditorName DisplayOrder="Western">
            <GivenName>J.M.</GivenName>
            <FamilyName>Walker</FamilyName>
          </EditorName>
        </Editor>
        <Affiliation ID="Aff1">
          <OrgName>School of Life Sciences University of Hertfordshire</OrgName>
          <OrgAddress>
            <City>Hatfield</City>
            <State>Hertfordshire, AL10 9AB</State>
            <Country>UK</Country>
          </OrgAddress>
        </Affiliation>
      </EditorGroup>
    </SeriesHeader>
    <Book Language="En">
      <BookInfo BookProductType="Contributed volume" ContainsESM="No" Language="En" MediaType="eBook" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
        <BookID>978-1-60327-527-9</BookID>
        <BookTitle>T Cell Protocols</BookTitle>
        <BookSubTitle>Second Edition</BookSubTitle>
        <BookVolumeNumber>514</BookVolumeNumber>
        <BookSequenceNumber>514</BookSequenceNumber>
        <BookDOI>10.1007/978-1-60327-527-9</BookDOI>
        <BookTitleID>145011</BookTitleID>
        <BookPrintISBN>978-1-58829-587-3</BookPrintISBN>
        <BookElectronicISBN>978-1-60327-527-9</BookElectronicISBN>
        <BookChapterCount>11</BookChapterCount>
        <BookCopyright>
          <CopyrightHolderName>Humana Press</CopyrightHolderName>
          <CopyrightYear>2009</CopyrightYear>
        </BookCopyright>
        <BookSubjectGroup>
          <BookSubject Code="SCL" Type="Primary">Life Sciences</BookSubject>
          <BookSubject Code="SCL14005" Priority="1" Type="Secondary">Biochemistry, general</BookSubject>
          <BookSubject Code="SCB14000" Priority="2" Type="Secondary">Immunology</BookSubject>
          <BookSubject Code="SCL16020" Priority="3" Type="Secondary">Cell Culture</BookSubject>
          <SubjectCollection Code="SUCO11642">Biomedical and Life Sciences</SubjectCollection>
        </BookSubjectGroup>
        <BookContext>
          <SeriesID>7651</SeriesID>
        </BookContext>
      </BookInfo>
      <BookHeader>
        <EditorGroup>
          <Editor AffiliationIDS="Aff2">
            <EditorName DisplayOrder="Western">
              <GivenName>Gennaro</GivenName>
              <Particle>De</Particle>
              <FamilyName>Libero</FamilyName>
            </EditorName>
            <Role>Dr</Role>
            <Contact>
              <Email>Gennaro.DeLibero@unibas.ch</Email>
            </Contact>
          </Editor>
          <Affiliation ID="Aff2">
            <OrgName>University of Basel</OrgName>
            <OrgAddress>
              <State>Basel</State>
              <Country>Switzerland</Country>
            </OrgAddress>
          </Affiliation>
        </EditorGroup>
      </BookHeader>
      <Chapter ID="Chap9" Language="En">
        <ChapterInfo ChapterType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="ChapterContentSeparately" OutputMedium="Online" TocLevels="0">
          <ChapterID>9</ChapterID>
          <ChapterNumber>Chapter 9</ChapterNumber>
          <ChapterDOI>10.1007/978-1-60327-527-9_9</ChapterDOI>
          <ChapterSequenceNumber>9</ChapterSequenceNumber>
          <ChapterTitle Language="En">Cytokine Multiplex Immunoassay: Methodology and (Clinical) Applications</ChapterTitle>
          <ChapterFirstPage>119</ChapterFirstPage>
          <ChapterLastPage>133</ChapterLastPage>
          <ChapterCopyright>
            <CopyrightHolderName>Humana Press, a part of Springer Science+Business Media, LLC</CopyrightHolderName>
            <CopyrightYear>2009</CopyrightYear>
          </ChapterCopyright>
          <ChapterGrants Type="Regular">
            <MetadataGrant Grant="OpenAccess"/>
            <AbstractGrant Grant="OpenAccess"/>
            <BodyPDFGrant Grant="Restricted"/>
            <BodyHTMLGrant Grant="Restricted"/>
            <BibliographyGrant Grant="Restricted"/>
            <ESMGrant Grant="Restricted"/>
          </ChapterGrants>
          <ChapterContext>
            <SeriesID>7651</SeriesID>
            <BookID>978-1-60327-527-9</BookID>
            <BookTitle>T Cell Protocols</BookTitle>
          </ChapterContext>
        </ChapterInfo>
        <ChapterHeader>
          <AuthorGroup>
            <Author AffiliationIDS="Aff3" CorrespondingAffiliationID="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Wilco</GivenName>
                <Particle>de</Particle>
                <FamilyName>Jager</FamilyName>
              </AuthorName>
              <Role>PhD</Role>
            </Author>
            <Author AffiliationIDS="Aff3">
              <AuthorName DisplayOrder="Western">
                <GivenName>Berent</GivenName>
                <FamilyName>Prakken</FamilyName>
              </AuthorName>
              <Role>Prof. MD, PhD</Role>
            </Author>
            <Author AffiliationIDS="Aff3 Aff4">
              <AuthorName DisplayOrder="Western">
                <GivenName>Ger</GivenName>
                <GivenName>T.</GivenName>
                <FamilyName>Rijkers</FamilyName>
              </AuthorName>
              <Role>PhD</Role>
            </Author>
            <Affiliation ID="Aff3">
              <OrgDivision>Department of Pediatric Immunology</OrgDivision>
              <OrgName>Wilhelmina Children’s Hospital, University Medical Center Utrecht</OrgName>
              <OrgAddress>
                <State>Utrecht</State>
                <Country>The Netherlands</Country>
              </OrgAddress>
            </Affiliation>
            <Affiliation ID="Aff4">
              <OrgName>Laboratory of Medical Microbiology and Immunology</OrgName>
              <OrgAddress>
                <Street>St. Antonius Hospital</Street>
                <State>Nieuwegein</State>
                <Country>The Netherlands</Country>
              </OrgAddress>
            </Affiliation>
          </AuthorGroup>
          <Abstract ID="Abs1" Language="En">
            <Heading>Abstract</Heading>
            <Para TextBreak="No">Subsets of T cells can be distinguished on basis of their cytokine production and secretion profile.</Para>
            <Para TextBreak="No">With the critical role of cytokines in the regulation of immune and inflammatory responses, cytokines hold the promise to become the ideal biomarkers to monitor development and progression of immune-mediated diseases, study the development of new therapeutic approaches (both in vitro and in vivo) and as outcome parameters. Because of the numerous interactions in the cytokine network, the pleiotropic actions and redundancy, it will be necessary to monitor the complete spectrum of cytokines. As such, the multiplex immunoassay (MIA) is the ideal technique for that purpose. This paper reviews the critical methodological steps of this technique, including the procedures for antibody coupling to beads and matrix effects of biological fluids and buffer solutions. The power and robustness of the MIA technique is illustrated by an analysis of cytokine profiles in juvenile idiopathic arthritis.</Para>
          </Abstract>
          <KeywordGroup Language="En">
            <Heading>Key words</Heading>
            <Keyword>Cytokines</Keyword>
            <Keyword>multiplex immunoassay</Keyword>
            <Keyword>Luminex</Keyword>
            <Keyword>juvenile idiopathic arthritis</Keyword>
          </KeywordGroup>
        </ChapterHeader>
        <Body>
          <Section1 ID="Sec1" OutputMedium="Online" Type="Introduction">
            <Heading>Introduction</Heading>
            <Para TextBreak="No">Primary activation of naive CD4<Superscript>+</Superscript> helper T lymphocytes (which are termed Th0 cells) on antigen presenting dendritic cells leads to differentiation into two major categories of T-helper cells: T-helper 1 cells (Th1) and T-helper 2 cells (Th2). Th1 and Th2 cells can be distinguished on basis of their cytokine production and secretion profile (<Emphasis Type="Bold">Fig.</Emphasis>
              <InternalRef RefID="Fig9_1_978-1-60327-527-9">
                <Emphasis Type="Bold">9.1</Emphasis>
              </InternalRef>). Accordingly, Th1 cells secrete the cytokines γ-interferon and interleukin-2 (IL-2), major cytokines for induction and regulation of the cellular immune response and for macrophage activation. Th2 cells produce and secrete IL-4, IL-5, and IL-13, cytokines which regulate the response of B lymphocytes. Regulatory T lymphocytes (see below) produce and secrete mainly IL-10 and/or transforming growth factor β (TGF-β). Recently, a novel Th subset has been defined, Th17 <CitationRef CitationID="CR1">(1</CitationRef>, <CitationRef CitationID="CR2">2)</CitationRef>. Driven by IL-23, Th17 cells produce the pro-inflammatory cytokine IL-17 (<Emphasis Type="Bold">Fig.</Emphasis>
              <InternalRef RefID="Fig9_1_978-1-60327-527-9">
                <Emphasis Type="Bold">9.1</Emphasis>
              </InternalRef>).
<Figure Category="Standard" Float="Yes" ID="Fig9_1_978-1-60327-527-9">
                <Caption Language="En">
                  <CaptionNumber>Fig. 9.1.</CaptionNumber>
                  <CaptionContent>
                    <SimplePara>Cytokine production pattern and regulation by subsets of CD4 T lymphocytes.</SimplePara>
                  </CaptionContent>
                </Caption>
                <MediaObject>
                  <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig1_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                </MediaObject>
              </Figure>
            </Para>
            <Para TextBreak="No">Abnormalities in regulatory circuits as found in autoimmune and allergic diseases are reflected in the cytokine pattern in blood as well as in in vitro systems. Rheumatoid arthritis is considered to be a so-called Th1-mediated autoimmune disease. In peripheral blood of these patients, increased concentrations of typical Th1 cytokines as γ-interferon and IL-2 are found <CitationRef CitationID="CR3">(3)</CitationRef>. Also pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, and TNFα are increased as compared to other forms of arthritis and to healthy controls <CitationRef CitationID="CR3">(3</CitationRef>, <CitationRef CitationID="CR4">4)</CitationRef>. Moreover, also other cytokines, such as the IL-17 mentioned above, can be increased <CitationRef CitationID="CR4">(4)</CitationRef>. Not always (or maybe even: most of the times not) is the cytokine pattern as found in blood a good reflection of the situation at the site of active inflammation, in case of RA the affected joints. In such as case analysis of cytokines in synovial fluid is indicated.</Para>
            <Para TextBreak="No">The two major subpopulations of T lymphocytes are the CD4 (helper) cells and the CD8 cells. The CD8 T lymphocyte population includes cytotoxic T lymphocytes and until the mid-1980s of the last century within this subset also suppressor T lymphocytes were defined. Research into suppressor T lymphocytes appeared to be difficult and gradually faded away. Recently there has been a modest revival of CD8 regulatory cells. These cells are capable to recognize autoantigens, presented by non-classical class 1 MHC molecules (HLA-E) on activated, autoreactive T lymphocytes, and to suppress or kill these cells <CitationRef CitationID="CR5">(5)</CitationRef>.</Para>
            <Para TextBreak="No">Within the CD4<Superscript>+</Superscript> T lymphocytes a separate category of regulatory T lymphocytes is formed by the CD4<Superscript>+</Superscript>CD25<Superscript>+</Superscript> regulatory T cells (Tregs) <CitationRef CitationID="CR6">(6</CitationRef>, <CitationRef CitationID="CR7">7)</CitationRef>. Tregs have the ability to suppress T cell responses and thus can play a pivotal role in the regulation of the immune response.</Para>
            <Para TextBreak="No">The discovery of CD4<Superscript>+</Superscript>CD25<Superscript>+</Superscript> Tregs came from experiments in mice in which it was found that neonatal thymectomy caused a multiorgan autoimmune disease. The crucial experiments were conducted in the laboratory of Sakaguchi, where it was found that injection of CD25<Superscript>-</Superscript> T lymphocytes into nude mice leads to a systemic autoimmune disease with signs of van colitis, gastritis, autoimmune diabetes, and thyroiditis <CitationRef CitationID="CR8">(8)</CitationRef>. Addition of low numbers of CD4<Superscript>+</Superscript>CD25<Superscript>+</Superscript> T lymphocytes to the CD25<Superscript>−</Superscript> T lymphocytes completely prevented development of the disease <CitationRef CitationID="CR8">(8)</CitationRef>. Also in humans CD4<Superscript>+</Superscript>CD25<Superscript>+</Superscript> T lymphocytes, despite constituting only a small fraction of CD4<Superscript>+</Superscript> cells, are important regulatory cells.</Para>
            <Para TextBreak="No">With the critical role of cytokines in the regulation of immune and inflammatory responses, cytokines hold the promise to become the ideal biomarkers to monitor development and progression of immune-mediated diseases, study the development of mediation (both in vitro and in vivo) and as outcome parameters. Because of the numerous interactions in the cytokine network, the pleiotropic actions and redundancy, it will be necessary to monitor the complete spectrum of cytokines. As such, the multiplex immunoassay is the ideal technique for that purpose.</Para>
            <Para TextBreak="No">Cytokine production by T lymphocytes in principle can be measured at three levels: mRNA, intracellular production (most often expressed as the frequency of cells which produce a particular cytokine) or at the level of the actual secreted cytokines. Every assay has its pro’s and con’s with large variations in amount of cells, time and money required. The ideal assay once has been characterized by Vignalli in that it should require a minimal amount of cells, time and money but also should be specific, sensitive, simple (the KISS principle; keep it simple, stupid) and reliable, or “robust” as today’s alternative for reliability <CitationRef CitationID="CR9">(9)</CitationRef>. The multiplex immunoassay for measurement of cytokines fulfills most of these criteria for the perfect assay as will be indicated below. We advocate the acronym MIA for this multiplex immunoassay. MIA would be a logical extension of a series of laboratory techniques that began with RIA (for radio immunoassay) and was continued with ELISA (enzyme-linked immunosorbent assay).</Para>
          </Section1>
          <Section1 ID="Sec2" OutputMedium="Online">
            <Heading>Materials</Heading>
            <Section2 ID="Sec3" OutputMedium="Online">
              <Heading>Covalent Coupling of the Capture Antibodies</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Antibodies and recombinant proteins (<Emphasis Type="Bold">Table</Emphasis>
                        <InternalRef RefID="Tab9_1_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.1</Emphasis>
                        </InternalRef>)<Table Float="Yes" ID="Tab9_1_978-1-60327-527-9">
                          <Caption Language="En">
                            <CaptionNumber>Table 9.1</CaptionNumber>
                            <CaptionContent>
                              <SimplePara>Reagents used for the multiplex immunoassay</SimplePara>
                            </CaptionContent>
                          </Caption>
                          <tgroup cols="8">
                            <colspec align="left" colname="col1" colnum="1"/>
                            <colspec align="left" colname="col2" colnum="2"/>
                            <colspec align="left" colname="col3" colnum="3"/>
                            <colspec align="left" colname="col4" colnum="4"/>
                            <colspec align="left" colname="col5" colnum="5"/>
                            <colspec align="left" colname="col6" colnum="6"/>
                            <colspec align="left" colname="col7" colnum="7"/>
                            <colspec align="left" colname="col8" colnum="8"/>
                            <thead>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>Mediator</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>Protein</SimplePara>
                                </entry>
                                <entry colname="col3" nameend="col5" namest="col3" valign="top">
                                  <SimplePara>Capture antibody</SimplePara>
                                </entry>
                                <entry colname="col4" nameend="col8" namest="col6" valign="top">
                                  <SimplePara>Detection antibody</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top"/>
                                <entry colname="col2" valign="top">
                                  <SimplePara>Source</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>Clone</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Species</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>Source</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>Clone</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Species</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>Source</SimplePara>
                                </entry>
                              </row>
                            </thead>
                            <tbody>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-2</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>5344.111</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>B33-2</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-4</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>RD</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>8D4-8</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>EB</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>MP4-25D2</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>EB</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-5</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>BS</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>JES1-39D10</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>BS</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>JES1-5A10</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-10</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>JES3-19F1</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>JES3-12G8</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-13</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>NIBSC</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>CLB/IL13-1</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>SQ</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>CLB/13-2</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>SQ</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-17</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>RD</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>41809.111</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>RD</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>Polyclonal</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Goat</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>RD</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IL-23</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>EB</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>eBio473P19</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Rat</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>EB</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>C8.6</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>EB</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>TNFα</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>SM</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>MAb1</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>MAb11</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                              </row>
                              <row>
                                <entry colname="col1" valign="top">
                                  <SimplePara>IFNγ</SimplePara>
                                </entry>
                                <entry colname="col2" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col3" valign="top">
                                  <SimplePara>NIB42</SimplePara>
                                </entry>
                                <entry colname="col4" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col5" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                                <entry colname="col6" valign="top">
                                  <SimplePara>4S.B3</SimplePara>
                                </entry>
                                <entry colname="col7" valign="top">
                                  <SimplePara>Mouse</SimplePara>
                                </entry>
                                <entry colname="col8" valign="top">
                                  <SimplePara>BD</SimplePara>
                                </entry>
                              </row>
                            </tbody>
                          </tgroup>
                          <tfooter>
                            <SimplePara>The reagents listed were obtained from the source indicated by the following abbreviations; BD = BD Biosciences (San Diego, CA, USA), BS = Bioscource/Invitrogen (Nivelles, Belgium), EB = eBioscience (San Diego, CA, USA), NIBSC = National Institute for Biological Standards and Control (Potters Bar, UK), RD = R&amp;D Systems (Abington, UK), SM = Strathmann Biotec (Hamburg, Germany), SQ = Sanquin (Amsterdam, The Netherlands).</SimplePara>
                          </tfooter>
                        </Table>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">
                        <Emphasis Type="Italic">N</Emphasis>-hydroxy-sulfosuccinimide (Sulfo-NHS; Pierce Rockford, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC; Pierce, Rockford, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">xMAP COOH microspheres (Biorad Laboratories, Hercules USA) <Emphasis Type="Italic">Light sensitive</Emphasis>
                      </Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Vivaspin 500, 10,000 Kd (Vivascience, Lincoln, UK)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Phosphate-buffered saline 0.1 M, pH 7.2 (PBS)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PBS, 0.05% Tween 20</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PBS, 0.05% Tween 20, 1% bovine serum albumin</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PBS, 1% BSA, 0.1% sodium azide</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Goat anti mouse IgG fluorescein isothiocyanate (FITC; BD Bioscience, San Diego, USA)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec4" OutputMedium="Online">
              <Heading>Multiplex Immunoassay</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Coupled microspheres, biotinylated antibodies and recombinat proteins (<Emphasis Type="Bold">Table</Emphasis>
                        <InternalRef RefID="Tab9_1_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.1</Emphasis>
                        </InternalRef>)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Streptavidin R-phycoerythrin (SA-PE; BD Biosciences, San Diego, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PDVF filterplates (96 well) (Millipore, Billerica, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">High Performance ELISA Buffer (HPE, Sanquin, Amsterdam, The Netherlands)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Serum diluent (R&amp;D Systems, Abington, UK)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Bio-plex Suspension Array System Luminex (xMAP-based platform, Biorad Laboratories, Hercules, USA)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec5" OutputMedium="Online">
              <Heading>Matrix Effect</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PBS, 5% FCS (Gibco / Invitogen, Gaithersburg, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">PBS, 5% human AB serum (Sanquin Bloodbank, Amsterdam, The Netherlands)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">AIM-V (Gibco/ Invitrogen, Gaithersburg, USA) supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RPMI1640 (Gibco/ Invitrogen, Gaithersburg, USA) supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">IMDM (Gibco/ Invitrogen, Gaithersburg, USA) supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">D-MEM (Gibco/ Invitrogen, Gaithersburg, USA) supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Various recombinant proteins (5 ng/ml, <Emphasis Type="Bold">Table</Emphasis>
                        <InternalRef RefID="Tab9_1_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.1</Emphasis>
                        </InternalRef>)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec6" OutputMedium="Online">
              <Heading>Cell Culture for Cytokine Analysis</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Ficoll (1.077 g/cm<Superscript>3</Superscript>; Amersham Pharmacia Biotech AB, Uppsala, Sweden)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RPMI1-640 supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">CD3 (clone OKT3, eBioscience)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">CD28 (clone CD28.2, eBioscience)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Tetanus toxoid (TT; National Institute of Public Health and the Environment [RIVM], Bilthoven, The Netherlands)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec7" OutputMedium="Online">
              <Heading>Assay Performance</Heading>
              <Para TextBreak="No">
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Ficoll (1.077 g/cm<Superscript>3</Superscript>; Amersham Pharmacia Biotech AB, Uppsala, Sweden)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">RPMI1640 supplemented with 5% FCS</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Concanavalin A (ConA; Calbiochem, La Jolla, USA)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Tetanus toxoid (TT; National Institute of Public Health and the Environment [RIVM], Bilthoven, The Netherlands)</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Phytohemagglutinin (PHA; Murex Biotech, Dartford, UK)</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec8" OutputMedium="Online">
            <Heading>Methods</Heading>
            <Para TextBreak="No">The methods described below outline (<Emphasis Type="Bold">Section 3.1</Emphasis>) the covalent coupling of the capture antibodies to the carboxylated microspheres, (<Emphasis Type="Bold">Section 3.2</Emphasis>) the multiplex immunoassay itself, (<Emphasis Type="Bold">Section 3.3</Emphasis>) any matrix effects that may occur, (<Emphasis Type="Bold">Section 3.4</Emphasis>) implementation of cytokines measurements in cell culture supernatants and (<Emphasis Type="Bold">Section 3.5</Emphasis>) assay performance overtime.</Para>
            <Section2 ID="Sec9" OutputMedium="Online">
              <Heading>Covalent Coupling of Antibodies to the Microspheres</Heading>
              <Para TextBreak="No">All antibody pairs used were directed against different non-competing epitopes of their respective cytokines and were purchased from different commercial sources (<Emphasis Type="Bold">Table</Emphasis>
                <InternalRef RefID="Tab9_1_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.1</Emphasis>
                </InternalRef>). If necessary, antibodies were reconstituted in phosphate-buffered saline (PBS), pH 7.4. Sodium azide (NaN3) was removed from the capture antibodies with a Vivaspin 500 concentrator with a 10,000-molecular-weight cutoff polyethersulfone membrane (Vivascience, Lincoln, UK), which was spun three times at 10,000 × <Emphasis Type="Italic">g</Emphasis> with PBS used as the wash matrix. All recombinant proteins except IL-13 were reconstituted in PBS, pH 7.4, containing 1% bovine serum albumin (BSA; Sigma-Aldrich, Zwijndrecht, The Netherlands) to a concentration of 10 µg/ml. IL-13 was reconstituted to a concentration of 1 µg/ml. All proteins were aliquoted and stored at –80°C. Covalent coupling of the capture antibodies to the microspheres was performed by following the procedures recommended by Luminex Corporation (Austin, USA, <Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig9_2_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.2</Emphasis>
                </InternalRef>
                <Emphasis Type="Bold">A</Emphasis>) using <Emphasis Type="Italic">N</Emphasis>-hydroxy-sulfosuccinimide (Sulfo-NHS; Pierce Rockford, USA) and 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC; Pierce, Rockford, USA), as follows:
<Figure Category="Standard" Float="Yes" ID="Fig9_2_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 9.2.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Flow chart of coupling procedure of anti-cytokine antibodies to beads (panel <Emphasis Type="Bold">A</Emphasis>) and flowcytometric analysis of coupled beads (panel <Emphasis Type="Bold">B</Emphasis>). Open histograms, uncoupled beads, filled histograms, beads coupled with (from <Emphasis Type="Italic">top</Emphasis> to <Emphasis Type="Italic">bottom</Emphasis>) antibodies against IFNγ, IL-4, or IL-17, respectively. FITC fluorescence intensity is plotted on the <Emphasis Type="Italic">X</Emphasis>-axis, the relative number of beads on the <Emphasis Type="Italic">Y</Emphasis>-axis.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig2_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
                <OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The microspheres stock solutions were dispersed in a sonification bath for 1–2 min. An aliquot of 2.5 ×10<Superscript>6</Superscript> microspheres was resuspended in microtiter tubes (Eppendorf, Hamburg, Germany) containing 0.1 M sodium phosphate buffer, pH 6.1 (phosphate buffer), to a final volume of 80 µl.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">This suspension was mixed until a homogeneous distribution of the microspheres was observed.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Solutions of Sulfo-NHS and EDC, both at 50 mg/ml, were freshly prepared in phosphate buffer, and 10 µl of each solution was sequentially added to stabilize the reaction and activate the microspheres.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">This suspension was incubated for 10 min at room temperature and then resuspended in 250 µl of PBS containing 50 µg of antibody (<Emphasis Type="Italic">see</Emphasis>
                        <Emphasis Type="Bold">Note 1</Emphasis>).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The mixture was incubated overnight in the dark with continuous shaking.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Microspheres were then incubated with 250 µl of PBS-0.05% Tween 20 for 4 h at RT.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After aspiration, the beads were blocked with 1 ml of PBS-1% BSA-0.1% sodium azide.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>8.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The microspheres were counted with a hemacytometer and stored at a final concentration of 10<Superscript>7</Superscript> microspheres per ml in the dark at 4°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>9.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Coupling efficiency of monoclonal antibodies was tested by staining 5,000 microspheres with either fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin G (IgG; BD Biosciences, San Diego, CA, USA) or FITC-conjugated goat anti-rat IgG antibodies (Zymed Laboratories, San Francisco, CA, USA).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>10.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">When the microspheres are analyzed using a regular flow cytometer before and after coupling a clear positive signal is found on the coupled microspheres. Representative examples of flow cytometric analysis of beads before and after coupling of anti-IFNγ, anti-IL-4, and anti-IL-17 antibodies are displayed in <Emphasis Type="Bold">Fig.</Emphasis>
                        <InternalRef RefID="Fig9_2_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.2B</Emphasis>
                        </InternalRef>.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec10" OutputMedium="Online">
              <Heading>Multiplex Cytokine Assays</Heading>
              <Para TextBreak="No">Calibration curves from recombinant cytokine standards were prepared with twofold dilution steps (13 points and a blank, <Emphasis Type="Italic">see</Emphasis>
                <Emphasis Type="Bold">Note 2</Emphasis>) in serum diluent (R&amp;D Systems, Abington, UK). Samples were measured, and blank values were subtracted from all readings. All assays were carried out directly in a 96-well PDVF filterplates (Millipore, Billerica, USA) at room temperature and protected from light.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">A mixture containing 5,000 microspheres per cytokine (total volume 10 µl/well) was incubated for 1 h.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Next 10 µl/well of a cocktail of biotinylated antibodies (16.5 ng of each biotinylated antibody) was added and incubated for an additional hour.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">All incubations are performed at room temperature under continuous shaking.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Beads were washed twice with PBS-1% BSA-0.05% Tween 20 in order to remove any residual unbound antibody.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After 10 min of incubation with 100 ul Streptavidin R-phycoerythrin (SA-PE; BD Biosciences, San Diego, USA) in PBS (50 ng/well) and washing with PBS-1% BSA-0.05% Tween 20, the fluorescence intensity of the beads was measured in a final volume of 100 µl of HPE buffer (High Performance ELISA buffer; Sanquin, Amsterdam, The Netherlands).</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
              <Para TextBreak="No">Measurements and data analysis of all assays were performed with the BioPlex system in combination with the Bio-Plex Manager software (version 4.1) (Bio-plex Suspension Array system Luminex (xMAP based platform, Biorad Laboratories, Hercules, USA). This system distinguishes and classifies each microsphere by making use of the specific fluorescence dyes that are internalized in the microspheres. The SA-PE reporter signal does not interfere with the classification signals. A flow chart of the complete procedure is given in <Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig9_3_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.3</Emphasis>
                </InternalRef>.
<Figure Category="Standard" Float="Yes" ID="Fig9_3_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 9.3.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Flow chart of cytokine multiplex immunoassay.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig3_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
              <Para TextBreak="No">Accuracy of a quantitative cytokine immunoassay depends, amongst others, on the quality of the standard curves. These curves consist of a series (ranging from 2 to 13) of known amounts of natural or recombinant cytokine. In general, the cytokine concentrations are plotted versus absorbance or fluorescence intensity and, subsequently, this plot is used for a mathematically approach for curve fitting. An example of standard curves for Th1, Th2 and Treg/Th 17 subset are shown by <Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig9_4_978-1-60327-527-9">9.4</InternalRef>. The type of curve fitting has a direct effect on the accuracy of the results. The most common mathematical approach (often used in ELISA) is the linear regression model. When the biological range of cytokines of the specimens are within the linear range of the standard curve, this linear regression model is appropriate. Linear regression is a model which is simple and can be based on as few as three data points <CitationRef CitationID="CR10">(10)</CitationRef>. However, when the data are outside the linear part of the standard curve, the samples have to be diluted and reanalyzed. However, bead-based assays have a broader dynamic range as ELISA which range between 3 and 4 log scale. A broader dynamic range minimizes the number of samples that have to be rerun and reanalyzed. Though, with a broad range standard curve, a linear regression model will not be sufficient to create a large linear part of the standard curves. Therefore a non-linear regression model with either a four-parameter (4PL) or a five-parameter (5PL) approach is to be preferred <CitationRef CitationID="CR11">(11)</CitationRef>.
<Figure Category="Standard" Float="Yes" ID="Fig9_4_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 9.4.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Standard calibration curves for Th1 (<Emphasis Type="Italic">left panel</Emphasis>), Th2 (<Emphasis Type="Italic">middle panel</Emphasis>) and regulatory T cell / Th17 cytokines (<Emphasis Type="Italic">right panel</Emphasis>). Recombinant or purified cytokines, in a concentration range of 2.4–5,000 pg/ml were incubated with relevant beads and detection antibodies and analyzed by MIA. Data are derived from a single, representative 30-plex experiments. For clarity, IL-2, TNFα, and IFNγ curves are grouped (as Th1 cytokines), as are IL-4, IL-5, and IL-13 (as Th2 cytokines) and IL-10, IL-23, and IL-17 (Treg/Th17).</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig4_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
            </Section2>
            <Section2 ID="Sec11" OutputMedium="Online">
              <Heading>Matrix Effects</Heading>
              <Para TextBreak="No">To asses interference of different matrices, widely used cell culture media (AIM-V, RPMI1640, IMDM, an D-MEM, all supplemented with 5% FCS) were spiked with a fixed amount (5 ng/ml) of recombinant IL-2, IL-4, IL-10, TNFα, and IFNγ (as indicated by the material <Emphasis Type="Bold">Section 2.3</Emphasis>). Next both the spiked sample and the culture media was measured in triplicates over a period of 3 days. The signal/noise ratio was calculated by dividing the mean fluorescence intensity (MFI) of the spiked sample by the MFI of the media alone. The ideal assay will be formed when a high signal occurs in the spiked sample in combination with a low-background signal (<Emphasis Type="Bold">Table</Emphasis>
                <InternalRef RefID="Tab9_2_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.2</Emphasis>
                </InternalRef>). In our example, the serum diluent yielded the best result. However, since this is a serum diluent developed for ELISA purposes, it is not very suitable for analysis of cell culture supernatants. Because of the rather large matrix effects that can be found, we strongly recommend to construct the calibration curves always in the same tissue culture medium as used for the actual cell cultures themselves.
<Table Float="Yes" ID="Tab9_2_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Table 9.2</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Signal noise ratios obtained in various tissue culture media</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <tgroup cols="2">
                    <colspec align="left" colname="col1" colnum="1"/>
                    <colspec align="left" colname="col2" colnum="2"/>
                    <thead>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>Medium</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>Signal/noise ratio</SimplePara>
                        </entry>
                      </row>
                    </thead>
                    <tbody>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>5% Human AB in PBS</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>206 ± 28</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>5% FCS in PBS</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>113 ± 11</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>AIM-V</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>365 ± 45</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>D-MEM</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>149 ± 56</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>IMDM</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>211 ± 21</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>RPMI1640</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>293 ± 34</SimplePara>
                        </entry>
                      </row>
                      <row>
                        <entry colname="col1" valign="top">
                          <SimplePara>Serum diluent</SimplePara>
                        </entry>
                        <entry colname="col2" valign="top">
                          <SimplePara>943 ± 41</SimplePara>
                        </entry>
                      </row>
                    </tbody>
                  </tgroup>
                  <tfooter>
                    <SimplePara>Different culture media and buffers were spiked with 5 ng/ml IL-2, IL-4, IL-10, TNFα, and IFNγ. Next spiked samples and the culture media were measured in triplicates over a period of 3 days. The signal/noise ratio was calculated by dividing the mean fluorescence intensity (MFI) of the spiked sample by the MFI of the media alone.</SimplePara>
                  </tfooter>
                </Table>
              </Para>
            </Section2>
            <Section2 ID="Sec12" OutputMedium="Online">
              <Heading>Analysis of In Vitro Cytokine Production Patterns</Heading>
              <Para TextBreak="No">Application of the MIA technique on supernatants of in vitro activated T cells allows semi-high throughput analysis of cytokine responses, again with only small sample sizes required. As an example of the power of the technique the data of our analysis of immunodysregulation in an autoimmune disease of childhood will be presented.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Heparinized blood samples were collected from three patients with juvenile idiopathic arthritis who visited the outpatient clinic of at our hospital, as well as from three healthy control donors. Informed consent was obtained either from parents or directly from the patients when they were older than 12 years.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Peripheral blood mononuclear cell (PBMC) were isolated by Ficoll density gradient centrifugation (Ficoll 1.077 g/cm<Superscript>3</Superscript>; Amersham Pharmacia Biotech AB, Uppsala, Sweden).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">All cultures were performed in RPMI 1640 tissue culture medium supplemented 5% heat-inactivated FCS.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Cells were cultured at 2 ×10<Superscript>5</Superscript> cells per well and incubated for 24 h at 37°C in either RPMI medium alone, with 1.5 µg/ml of tetanus toxoid (TT; National Institute of Public Health and the Environment [RIVM], Bilthoven, The Netherlands), or with plate bound CD3/CD28.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">To that end round-bottomed microtiter plates were coated with 1 µg CD3 and 1.5 µg CD28; clones OKT2 and CD28.2, respectively, both from eBioscience) per well during 1 h at 37°C.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>6.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">At the end of the culture period, cell-free supernatants were collected and stored at −80°C until analysis.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>7.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Cytokine analysis was performed using the multiplex immunoassay as described in <Emphasis Type="Bold">Section 3.2</Emphasis>.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
              <Para TextBreak="No">The mathematic analysis of the obtained cytokine response can be performed using various different statistical packages (<Emphasis Type="Italic">see</Emphasis>
                <Emphasis Type="Bold">Note 3</Emphasis>). However, using a standard statistical approach, comparison can only be made on single cytokine level, loosing many of the advantages of a multiplex assay. Therefore, as shown in <Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig9_5_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.5</Emphasis>
                </InternalRef>, a heat map can be constructed using raw data of each individual showing all cytokines. Using this approach, it is directly apparent if cytokines are up or down regulated in various individuals and to detect groups of cytokines which cluster together, without any specific statistical approach. This is very useful since the MIA will generate large amounts of data in a short period of time. Here we show after 24 h using TT or CD3/CD28 significant cytokine released into the culture supernatant. The data in <Emphasis Type="Bold">Fig.</Emphasis>
                <InternalRef RefID="Fig9_6_978-1-60327-527-9">
                  <Emphasis Type="Bold">9.6</Emphasis>
                </InternalRef> illustrate that during a recall response to tetanus toxoid, several cytokines are upregulated, including IL-2, TNF-α, IFN-γ, IL-5, IL-13, IL-10, IL-23, and IL-17. The observed cytokine levels vary between individuals, probably depending on the vaccination status and/or in vivo exposure. Following polyclonal T cell activation with a combination of CD3 and CD28 antibodies, cultures of PBMCs of both JIA patients as well as healthy controls generated higher levels of most of the cytokines mentioned above, now also including IL-4. Next to the heat map approach for statistical analysis, a cluster analysis can be performed but such an analysis requires larger datasets. At any rate, the MIA technique is capable to detect and quantify the in vitro cytokine response of T lymphocytes, activated either polyclonally or with specific recall-antigens.
<Figure Category="Standard" Float="Yes" ID="Fig9_5_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 9.5.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Multiplex immunoassay of T cell cytokines in supernatants of peripheral blood mononuclear cells of healthy controls (HC) or patients with juvenile idiopathic arthritis (JIA) which were cultured with tetanus toxoid, with a combination of CD3 and CD28 antibodies or were left unstimulated. The individual cytokine concentration of an individual culture is indicated according to the pseudocolor scale on the right hand side of the figure.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig5_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
                <Figure Category="Standard" Float="Yes" ID="Fig9_6_978-1-60327-527-9">
                  <Caption Language="En">
                    <CaptionNumber>Fig. 9.6.</CaptionNumber>
                    <CaptionContent>
                      <SimplePara>Standard curves and intra-assay variation. <Emphasis Type="Italic">Left panel</Emphasis> shows the data points to be used for construction of a (12 point) calibration curve. Data of four independent experiments, run several months apart, are shown. <Emphasis Type="Italic">Right panel</Emphasis> shows longitudinal variation in the observed concentration of IL-2 as measured in a positive control sample (consisting of the supernatant of polyclonal activated mononuclear cells, aliquotted and stored at –80°C). The 50 runs were performed over a period of 18 months. <Emphasis Type="Italic">Horizontal drawn line</Emphasis> is the median value, <Emphasis Type="Italic">dotted lines</Emphasis> are + and –30% of the median.</SimplePara>
                    </CaptionContent>
                  </Caption>
                  <MediaObject>
                    <ImageObject Color="BlackWhite" FileRef="MediaObjects/978-1-60327-527-9_9_Fig6_HTML.jpg" Format="JPEG" Rendition="HTML" Type="Linedraw"/>
                  </MediaObject>
                </Figure>
              </Para>
            </Section2>
            <Section2 ID="Sec13" OutputMedium="Online">
              <Heading>Assay Performance</Heading>
              <Para TextBreak="No">To asses overtime assay performance an internal control sample was run every assay.<OrderedList>
                  <ListItem>
                    <ItemNumber>1.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">The internal control was made by isolating cells as described at <Emphasis Type="Bold">Section 3.4</Emphasis>.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>2.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">To induce a cytokine profile cells were cultured at 2 ×10<Superscript>5</Superscript> cells per well and incubated for 36 h at 37°C in RPMI medium supplemented with 2.5 μg/ml concanavalin A (ConA), 1.5 μg/ml of tetanus toxoid and 7 μg/ml of phytohemagglutinin (PHA).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>3.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">At the end of the culture period, supernatants were collected and stored at −80°C until analysis.</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>4.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">After each run data was plotted and a Levy–Jennings plot was constructed (<Emphasis Type="Bold">Fig.</Emphasis>
                        <InternalRef RefID="Fig9_6_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.6</Emphasis>
                        </InternalRef>).</Para>
                    </ItemContent>
                  </ListItem>
                  <ListItem>
                    <ItemNumber>5.</ItemNumber>
                    <ItemContent>
                      <Para TextBreak="No">Recombinant cytokines that are used to construct standard curves can degrade during long time storage. This will result in a downward shift of MFI from the standard curves. Therefore it is useful to create overlays from standard curves over time (<Emphasis Type="Bold">Fig.</Emphasis>
                        <InternalRef RefID="Fig9_6_978-1-60327-527-9">
                          <Emphasis Type="Bold">9.6</Emphasis>
                        </InternalRef>). Furthermore when this phenomenon occur absolute values of an internal control sample will increase overtime. Thus assay performance can simply monitored using a single control sample.</Para>
                    </ItemContent>
                  </ListItem>
                </OrderedList>
              </Para>
            </Section2>
            <Section2 ID="Sec14" OutputMedium="Online">
              <Heading>Conclusions and Perspectives</Heading>
              <Para TextBreak="No">The multiplex immunoassay is a powerful technique for measurement of complex mixtures of cytokines in T cell culture supernatants or in blood or any other relevant biological fluid. We prefer to prepare our own beads for cytokine and chemokine analysis. In that way any available pair of antibodies against a given cytokine can be added directly to the panel and any combination of cytokines can be made. On a per cytokine per sample basis, this procedure is by far the most cost-effective. The total costs, excluding labor, are less than 50% of the lowest available commercial price. It does, however, require specific laboratory infrastructure and a certain turnover in order to become really cost-effective. For the more “casual” user of the technique, now several companies offer versatile and competitively priced kits for measurement of human or murine cytokines. Thus, multiplex analysis of T cell cytokines is within reach of everyone studying immunoregulation.</Para>
            </Section2>
          </Section1>
          <Section1 ID="Sec15" OutputMedium="Online">
            <Heading>Notes</Heading>
            <Para TextBreak="No">
              <OrderedList>
                <ListItem>
                  <ItemNumber>1.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">The water soluble Sulfo-NHS is used to modify a carboxyl group to an amine reactive NHS ester. This is accomplished by mixing the NHS with a carboxyl containing molecule and a dehydrating agent (EDC). The carboxyl group is present on the microspheres that are used for the multiplex immuno assay. EDC reacts with the carboxyl group first and forms an amine-reactive intermediate, an <Emphasis Type="Italic">O</Emphasis>-acylisurea. The intermediate is unstable in aqueous solutions and is therefore not useful in two-step conjugations procedures without stabilization of the intermediate using NHS <CitationRef CitationID="CR12">(12</CitationRef>, <CitationRef CitationID="CR13">13)</CitationRef>. Failure to react with an amine will result in hydrolysis of the intermediate, regeneration of the carboxyl, and release of an <Emphasis Type="Italic">N</Emphasis>-substituted urea. This will occur with prolonged incubation times (&gt;20 min). A side reaction is the formation of an <Emphasis Type="Italic">N</Emphasis>-acylurea, which is usefully restricted to carboxyl groups located in hydrophobic usually of antibodies <CitationRef CitationID="CR14">(14)</CitationRef>.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>2.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">Calibration curves can also be made based using a higher dilution factor and can go down to as low as 6 data points, since both 4PL and 5PL regression models require at least 6 data points. However, additional data points to create a standard curve will also result in a better and more accurate fit, and thus a more accurate quantitation across a broader range of the standard curve compared <CitationRef CitationID="CR10">(10)</CitationRef>. The difference between a 4PL and a 5PL logistic curve-fitting model is an addition parameter which is added for asymmetry in a 5PL model. This additional parameter provides a better fit when standard curves are not symmetrical. The choice of logistic regression that will yield the best fit of a given dataset is dependent on the shape of the standard curve <CitationRef CitationID="CR11">(11)</CitationRef>. When a sigmoidal curve is obtained there will no differences in outcome when samples are analyzed with either a 4PL or a 5PL regression model. However, when curves are not symmetrical due to low or high sensitivity of the antibody set used in the assay interpretation with a 5 PL regression model will yield better results <CitationRef CitationID="CR15">(15)</CitationRef>.</Para>
                  </ItemContent>
                </ListItem>
                <ListItem>
                  <ItemNumber>3.</ItemNumber>
                  <ItemContent>
                    <Para TextBreak="No">When cytokines from cell cultures are analyzed in cohorts (with or without stimulation) a large natural dynamic variation will be present. Due to this large biological variability in cytokine levels and non-Gaussian distribution it can be envisioned that a single or a few outliers in a population can scrutinize the data set when mean values are calculated. Therefore we recommend using geometric means when data is presented as well when heat maps are constructed with mean cytokine levels of a population.</Para>
                  </ItemContent>
                </ListItem>
              </OrderedList>
            </Para>
          </Section1>
        </Body>
        <BodyRef FileRef="BodyRef/PDF/978-1-60327-527-9_Chapter_9.pdf" OutputMedium="All" PDFType="Typeset" TargetType="OnlinePDF"/>
        <ChapterBackmatter>
          <Bibliography ID="Bib1">
            <Heading>References</Heading>
            <Citation ID="CR1">
              <CitationNumber>1.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H.</Initials>
                  <FamilyName>Park</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>Z.</Initials>
                  <FamilyName>Li</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>XO.</Initials>
                  <FamilyName>Yang</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17</ArticleTitle>
                <JournalTitle>Nat Immunol</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1133</FirstPage>
                <LastPage>41</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFamsb%2FO</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ni1261</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16200068</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133–41.</BibUnstructured>
            </Citation>
            <Citation ID="CR2">
              <CitationNumber>2.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>LE.</Initials>
                  <FamilyName>Harrington</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RD.</Initials>
                  <FamilyName>Hatton</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>PR.</Initials>
                  <FamilyName>Mangan</FamilyName>
                </BibAuthorName>
                <Etal/>
                <Year>2005</Year>
                <ArticleTitle Language="En">Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T-helper type 1 and 2 lineages</ArticleTitle>
                <JournalTitle>Nat Immunol</JournalTitle>
                <VolumeID>6</VolumeID>
                <FirstPage>1123</FirstPage>
                <LastPage>32</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2MXhtFamsb7J</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1038/ni1254</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16200070</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T-helper type 1 and 2 lineages. Nat Immunol 2005;6:1123–32.</BibUnstructured>
            </Citation>
            <Citation ID="CR3">
              <CitationNumber>3.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Jager</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BJ.</Initials>
                  <FamilyName>Prakken</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>JW.</Initials>
                  <FamilyName>Bijlsma</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Kuis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT.</Initials>
                  <FamilyName>Rijkers</FamilyName>
                </BibAuthorName>
                <Year>2005</Year>
                <ArticleTitle Language="En">Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies</ArticleTitle>
                <JournalTitle>J Immunol Methods</JournalTitle>
                <VolumeID>300</VolumeID>
                <FirstPage>124</FirstPage>
                <LastPage>35</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.jim.2005.03.009</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>15896801</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Jager W, Prakken BJ, Bijlsma JW, Kuis W, Rijkers GT. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J Immunol Methods 2005;300:124–35.</BibUnstructured>
            </Citation>
            <Citation ID="CR4">
              <CitationNumber>4.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Jager</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>EP.</Initials>
                  <FamilyName>Hoppenreijs</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>NM.</Initials>
                  <FamilyName>Wulffraat</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LR.</Initials>
                  <FamilyName>Wedderburn</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Kuis</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>BJ.</Initials>
                  <FamilyName>Prakken</FamilyName>
                </BibAuthorName>
                <Year>2007</Year>
                <ArticleTitle Language="En">Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study</ArticleTitle>
                <JournalTitle>Ann Rheum Dis</JournalTitle>
                <VolumeID>66</VolumeID>
                <FirstPage>589</FirstPage>
                <LastPage>98</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1136/ard.2006.061853</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>17170049</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Jager W, Hoppenreijs EP, Wulffraat NM, Wedderburn LR, Kuis W, Prakken BJ. Blood and synovial fluid cytokine signatures in patients with juvenile idiopathic arthritis: a cross-sectional study. Ann Rheum Dis 2007;66:589–98.</BibUnstructured>
            </Citation>
            <Citation ID="CR5">
              <CitationNumber>5.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>H.</Initials>
                  <FamilyName>Jiang</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>L.</Initials>
                  <FamilyName>Chess</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Regulation of immune responses by T cells</ArticleTitle>
                <JournalTitle>N Engl J Med</JournalTitle>
                <VolumeID>354</VolumeID>
                <FirstPage>1166</FirstPage>
                <LastPage>76</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD28XisFems74%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1056/NEJMra055446</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16540617</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Jiang H, Chess L. Regulation of immune responses by T cells. N Engl J Med 2006;354:1166–76.</BibUnstructured>
            </Citation>
            <Citation ID="CR6">
              <CitationNumber>6.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Hori</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>T.</Initials>
                  <FamilyName>Takahashi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <Year>2003</Year>
                <ArticleTitle Language="En">Control of autoimmunity by naturally arising regulatory CD4+ T cells</ArticleTitle>
                <JournalTitle>Adv Immunol</JournalTitle>
                <VolumeID>81</VolumeID>
                <FirstPage>331</FirstPage>
                <LastPage>71</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD2cXhvFaqsrY%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0065-2776(03)81008-8</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>14711059</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Hori S, Takahashi T, Sakaguchi S. Control of autoimmunity by naturally arising regulatory CD4+ T cells. Adv Immunol 2003;81:331–71.</BibUnstructured>
            </Citation>
            <Citation ID="CR7">
              <CitationNumber>7.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <NoArticleTitle/>
                <JournalTitle>Regulatory T cells: Meden Agan Immunol Rev</JournalTitle>
                <VolumeID>212</VolumeID>
                <FirstPage>5</FirstPage>
                <LastPage>7</LastPage>
              </BibArticle>
              <BibUnstructured>Sakaguchi S. Regulatory T cells: Meden Agan Immunol Rev 2006;212:5–7.</BibUnstructured>
            </Citation>
            <Citation ID="CR8">
              <CitationNumber>8.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>S.</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>N.</Initials>
                  <FamilyName>Sakaguchi</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Asano</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Itoh</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Toda</FamilyName>
                </BibAuthorName>
                <Year>1995</Year>
                <ArticleTitle Language="En">Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases</ArticleTitle>
                <JournalTitle>J Immunol</JournalTitle>
                <VolumeID>155</VolumeID>
                <FirstPage>1151</FirstPage>
                <LastPage>64</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK2MXntFWnurs%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>7636184</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995;155:1151–64.</BibUnstructured>
            </Citation>
            <Citation ID="CR9">
              <CitationNumber>9.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>DA.</Initials>
                  <FamilyName>Vignali</FamilyName>
                </BibAuthorName>
                <Year>2000</Year>
                <ArticleTitle Language="En">Multiplexed particle-based flow cytometric assays</ArticleTitle>
                <JournalTitle>J Immunol Methods</JournalTitle>
                <VolumeID>243</VolumeID>
                <FirstPage>243</FirstPage>
                <LastPage>55</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DC%2BD3cXmtlGksr8%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/S0022-1759(00)00238-6</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>10986418</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Vignali DA. Multiplexed particle-based flow cytometric assays. J Immunol Methods 2000;243:243–55.</BibUnstructured>
            </Citation>
            <Citation ID="CR10">
              <CitationNumber>10.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>HJ.</Initials>
                  <FamilyName>Motulsky</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>LA.</Initials>
                  <FamilyName>Ransnas</FamilyName>
                </BibAuthorName>
                <Year>1987</Year>
                <ArticleTitle Language="En">Fitting curves to data using nonlinear regression: a practical and nonmathematical review</ArticleTitle>
                <JournalTitle>FASEB J</JournalTitle>
                <VolumeID>1</VolumeID>
                <FirstPage>365</FirstPage>
                <LastPage>74</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:STN:280:DyaL1c%2Fls1SgtQ%3D%3D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>3315805</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Motulsky HJ, Ransnas LA. Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1987;1:365–74.</BibUnstructured>
            </Citation>
            <Citation ID="CR11">
              <CitationNumber>11.</CitationNumber>
              <BibChapter>
                <BibAuthorName>
                  <Initials>M.</Initials>
                  <FamilyName>Baud</FamilyName>
                </BibAuthorName>
                <Year>1993</Year>
                <ChapterTitle Language="En">Data analysis, mathematical modeling</ChapterTitle>
                <BibEditorName>
                  <Initials>RF.</Initials>
                  <FamilyName>Masseyeff</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>W.</Initials>
                  <FamilyName>Albert</FamilyName>
                </BibEditorName>
                <BibEditorName>
                  <Initials>NA.</Initials>
                  <FamilyName>Staines</FamilyName>
                </BibEditorName>
                <Eds/>
                <BookTitle>Methods of Immunological Analysis Volume 1: Fundamentals</BookTitle>
                <PublisherName>VCH Publishers Inc</PublisherName>
                <PublisherLocation>New York</PublisherLocation>
                <FirstPage>656</FirstPage>
                <LastPage>71</LastPage>
              </BibChapter>
              <BibUnstructured>Baud M. Data analysis, mathematical modeling. In: Masseyeff RF, Albert W, Staines NA, eds. Methods of Immunological Analysis Volume 1: Fundamentals. New York: VCH Publishers Inc, 1993:656–71</BibUnstructured>
            </Citation>
            <Citation ID="CR12">
              <CitationNumber>12.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>JV.</Initials>
                  <FamilyName>Staros</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>RW.</Initials>
                  <FamilyName>Wright</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>DM.</Initials>
                  <FamilyName>Swingle</FamilyName>
                </BibAuthorName>
                <Year>1986</Year>
                <ArticleTitle Language="En">Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions</ArticleTitle>
                <JournalTitle>Anal Biochem</JournalTitle>
                <VolumeID>156</VolumeID>
                <FirstPage>220</FirstPage>
                <LastPage>2</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaL28XkvFeku78%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0003-2697(86)90176-4</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>3740412</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Staros JV, Wright RW, Swingle DM. Enhancement by N-hydroxysulfosuccinimide of water-soluble carbodiimide-mediated coupling reactions. Anal Biochem 1986;156:220–2.</BibUnstructured>
            </Citation>
            <Citation ID="CR13">
              <CitationNumber>13.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>Z.</Initials>
                  <FamilyName>Grabarek</FamilyName>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>J.</Initials>
                  <FamilyName>Gergely</FamilyName>
                </BibAuthorName>
                <Year>1990</Year>
                <ArticleTitle Language="En">Zero-length crosslinking procedure with the use of active esters</ArticleTitle>
                <JournalTitle>Anal Biochem</JournalTitle>
                <VolumeID>185</VolumeID>
                <FirstPage>131</FirstPage>
                <LastPage>5</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaK3cXhtlGmtr0%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0003-2697(90)90267-D</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>2344038</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Grabarek Z, Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990;185:131–5.</BibUnstructured>
            </Citation>
            <Citation ID="CR14">
              <CitationNumber>14.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>R.</Initials>
                  <FamilyName>Timkovich</FamilyName>
                </BibAuthorName>
                <Year>1977</Year>
                <ArticleTitle Language="En">Detection of the stable addition of carbodiimide to proteins</ArticleTitle>
                <JournalTitle>Anal Biochem</JournalTitle>
                <VolumeID>79</VolumeID>
                <FirstPage>135</FirstPage>
                <LastPage>43</LastPage>
                <Occurrence Type="COI">
                  <Handle>1:CAS:528:DyaE2sXhsFags70%3D</Handle>
                </Occurrence>
                <Occurrence Type="DOI">
                  <Handle>10.1016/0003-2697(77)90387-6</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>869171</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>Timkovich R. Detection of the stable addition of carbodiimide to proteins. Anal Biochem 1977;79:135–43.</BibUnstructured>
            </Citation>
            <Citation ID="CR15">
              <CitationNumber>15.</CitationNumber>
              <BibArticle>
                <BibAuthorName>
                  <Initials>W.</Initials>
                  <FamilyName>Jager</FamilyName>
                  <Particle>de</Particle>
                </BibAuthorName>
                <BibAuthorName>
                  <Initials>GT.</Initials>
                  <FamilyName>Rijkers</FamilyName>
                </BibAuthorName>
                <Year>2006</Year>
                <ArticleTitle Language="En">Solid-phase and bead-based cytokine immunoassay: a comparison</ArticleTitle>
                <JournalTitle>Methods</JournalTitle>
                <VolumeID>38</VolumeID>
                <FirstPage>294</FirstPage>
                <LastPage>303</LastPage>
                <Occurrence Type="DOI">
                  <Handle>10.1016/j.ymeth.2005.11.008</Handle>
                </Occurrence>
                <Occurrence Type="PID">
                  <Handle>16481197</Handle>
                </Occurrence>
              </BibArticle>
              <BibUnstructured>de Jager W, Rijkers GT. Solid-phase and bead-based cytokine immunoassay: a comparison. Methods 2006;38:294–303.</BibUnstructured>
            </Citation>
          </Bibliography>
        </ChapterBackmatter>
      </Chapter>
    </Book>
  </Series>
</Publisher>
